Quick View
| Metric | Current Period | Same Period of Previous Year | YoY |
|---|---|---|---|
| Revenue | ¥255.2B | ¥251.9B | +1.3% |
| Operating Income | ¥12.9B | ¥12.7B | +2.2% |
| Ordinary Income | ¥13.1B | ¥12.0B | +9.6% |
| Net Income | ¥9.1B | ¥8.5B | +7.6% |
| ROE | 4.8% | 4.6% | - |
Executive Summary
For the cumulative Q3 period of the fiscal year ending March 2026, the Company posted higher revenue and profit, accompanied by improved profitability in its core business, although an increase in company-wide expenses constrained the improvement in the consolidated profit margin. Revenue was ¥255.2B（+1.3% YoY）, while operating income was ¥12.9B（+2.2% YoY）. Ordinary income was ¥13.1B（+9.6% YoY）, and net income was ¥9.1B（+7.6% YoY）, showing growth exceeding that of operating income due to contributions from foreign exchange gains and extraordinary income.
Factors Affecting Performance
【Revenue】Revenue was ¥255.2B, representing a modest +1.3% YoY increase. The core Contact Lenses and Care Products segment generated ¥254.6B（99.8% of total revenue）, up +1.5% YoY, while Other Businesses（eyewear, etc.）remained at ¥0.6B. Progress against the full-year forecast of ¥370.0B was 69.0%, requiring an additional ¥114.8B in Q4.
【Profit and Loss】Segment profit increased +17.2% from ¥24.8B to ¥29.0B, clearly demonstrating improved profitability in the core business. However, company-wide expenses increased from ¥12.1B to ¥16.2B, limiting growth in consolidated operating income to ¥12.9B（+2.2%）. Ordinary income increased +9.6%, boosted by ¥3.5B in non-operating income, including ¥2.0B in foreign exchange gains, while net income increased +7.6%, additionally supported by ¥0.8B in extraordinary income. As the operating income growth rate slightly exceeded the revenue growth rate, the Company can be viewed as having achieved higher revenue and profit.
Segment Analysis
The reporting structure consists of a single Contact Lenses and Care Products segment, which recorded external revenue of ¥254.6B（+1.5% YoY）, segment profit of ¥29.0B（+17.2% YoY）, and an improved segment profit margin of 11.4%（10.0% in the previous year）. Other categories（eyewear, intraocular lenses, etc.）generated revenue of ¥0.6B and profit of ¥0.1B, making a limited contribution to consolidated results. Despite improved profitability in the core business, company-wide expenses（administrative department costs）increased to ¥16.2B, leaving the consolidated operating margin at 5.1%. In Q3, goodwill of ¥7.29B was provisionally recognized as a result of the acquisitions of shares in the UK’s Scotlens Holdings Limited and China’s Shanghai Huanying Trading Co., Ltd.
Key Financial Metrics
【Profitability】The operating margin was 5.1% and the net profit margin was 3.5%; the SG&A ratio of 39.8% weighed on profitability relative to the gross margin of 44.9%. ROE was 4.8%, decomposed into a net profit margin of 3.5% × total asset turnover of 0.481x × financial leverage of 2.81x, with the low asset turnover being the primary factor.【Cash Flow Quality】Operating Cash Flow (OCF) was ¥20.7B, approximately 2.3x net income of ¥9.1B, although the cash conversion ratio relative to EBITDA of ¥36.1B remained at 0.57x.【Investment Efficiency】Capital expenditures of ¥16.7B were 0.72x depreciation and amortization of ¥23.2B, indicating an investment level focused more on maintenance than expansion. Inventories amounted to ¥73.3B, representing 13.8% of total assets and tying up funds.【Financial Soundness】The equity ratio was 35.6%, the current ratio was 103.2%, and the quick ratio was 67.4%. Interest-bearing debt was ¥188.5B, with Debt/EBITDA at 5.22x. Cash and deposits of ¥51.7B were only 0.39x short-term borrowings of ¥133.5B, indicating a high dependence on refinancing for short-term liquidity.
Cash Flow Analysis
Operating Cash Flow (OCF) was ¥20.7B, down -21.1% from ¥26.3B in the previous year, and was approximately 2.3x net income of ¥9.1B; however, an increase in inventories made a negative contribution of ¥14.3B, constraining cash generation. Investing CF was negative ¥22.0B, primarily consisting of capital expenditures of ¥16.7B and acquisitions of subsidiary shares of ¥0.5B. Financing CF was negative ¥19.7B. Although the net increase in short-term borrowings was ¥9.0B, repayments of long-term borrowings of ¥13.2B, lease liabilities of ¥11.0B, and dividends paid of ¥4.5B were sources of cash outflow. As a result, free cash flow was negative ¥1.3B, indicating that operating activities alone were insufficient to cover investment and shareholder returns.
Earnings Quality
Although the growth in ordinary income and net income exceeded that of operating income, part of this growth was supported by factors that cannot be considered fully recurring. Of the ¥3.5B in non-operating income, foreign exchange gains accounted for ¥2.0B, equivalent to approximately 15% of operating income of ¥12.9B. Extraordinary income of ¥0.8B（primarily gains on the sale of fixed assets）also boosted net income and should be treated as a temporary factor. OCF of ¥20.7B exceeded net income of ¥9.1B, and no tendency toward earnings inflation is evident from an accrual perspective. However, the increase in inventories is putting pressure on working capital, leaving room to improve the efficiency of earnings conversion into cash（OCF/EBITDA of 0.57x）.
Earnings Forecast and Guidance
Progress against the full-year forecast was 69.0% for revenue, 64.7% for operating income, 81.9% for ordinary income, and 82.3% for net income. While operating income progress was below the 75% benchmark for the Q3 stage, ordinary income and net income exceeded it, with increased reliance on non-operating income underlying the difference in progress. To achieve the full-year forecast, Q4 requires revenue of ¥114.8B and operating income of ¥7.1B, making additional operating income, in particular, a key challenge.
Shareholder Returns
The full-year dividend forecast is ¥15 per share. Since the Q2 dividend was ¥0, the structure is dependent on the year-end dividend. Based on forecast full-year net income of ¥11.0B, the payout ratio is approximately 41.2%, a sustainable level on an earnings basis. However, cumulative Q3 free cash flow was negative ¥1.3B, meaning that dividends for the period were not fully covered by OCF. No share repurchases were identified, and shareholder returns consist solely of dividends.
Risk Factors
-
Inventory Obsolescence Risk: Inventories amounted to ¥73.3B, representing 13.8% of total assets, and inventory days were relatively long at approximately 143 days. The potential for discounting and inventory write-downs in response to demand fluctuations is relatively high.
-
Refinancing and Liquidity Risk: Cash and deposits were ¥51.7B against short-term borrowings of ¥133.5B, resulting in a coverage ratio of only 0.39x. Together with a quick ratio of 67.4%, this indicates high sensitivity to changes in the financing environment.
-
Leverage and Interest Burden Risk: Interest-bearing debt was ¥188.5B, interest expense was ¥2.9B, and interest coverage was 4.5x, while Debt/EBITDA was 5.22x. In a rising interest-rate environment, the impact on net income and free cash flow could become relatively significant.
Industry Benchmark（Reference; Compiled by the Company）
Industry Benchmark（manufacturing）
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 5.1% | 8.6% (4.3%–12.7%) | −3.5pt |
| Net Profit Margin | 3.6% | 6.4% (2.8%–10.3%) | −2.9pt |
Profitability is below the industry median and does not reach the lower bound of the IQR.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate（YoY） | 1.3% | 3.3% (-2.1%–8.9%) | −2.0pt |
Revenue growth is below the industry median but remains within the IQR range.
※Source: Compiled by the Company
Key Points from the Earnings Results
-
The core Contact Lenses and Care Products segment posted segment profit growth of +17.2% against revenue growth of +1.5%, confirming improved profitability at the business level. At the same time, company-wide expenses increased by +¥4.1B YoY, limiting the improvement reflected in the consolidated operating margin of 5.1%.
-
Growth in ordinary income and net income was supported to a certain extent by temporary factors such as ¥2.0B in foreign exchange gains and ¥0.8B in extraordinary income. Excluding these factors, underlying profit growth would be close to the +2.2% operating income growth rate.
-
Goodwill of ¥7.29B was provisionally recognized following the acquisitions of subsidiaries in the UK and China. Although its scale is limited at 5.6% of net assets, the purchase price allocation remains undecided, making the subsequent progress of integration benefits and earnings contributions key areas to monitor.
This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.
---End of Report---
AI Financial Analysis
Executive Summary
Seed delivered a modest but high-quality earnings improvement through FY2026 Q3, although balance-sheet liquidity and working-capital intensity remain material constraints. Revenue increased 1.3% year on year to ¥25.52bn, while operating income rose 2.2% to ¥1.29bn. Ordinary income increased faster, by 9.6% to ¥1.31bn, supported in part by ¥0.20bn of foreign-exchange gains. Profit attributable to owners rose 9.8% to ¥0.905bn, equivalent to EPS of ¥29.93. Gross profit increased 4.7% to ¥11.45bn despite limited top-line growth. The gross margin expanded by approximately 145bp year on year to 44.9%, from about 43.4%, indicating improved product mix, pricing, procurement, or manufacturing-cost absorption. However, SG&A rose 5.1%, materially faster than revenue growth, and absorbed much of the gross-profit improvement. Consequently, the operating margin improved only approximately 4bp to 5.1%, remaining near the lower end of the stated profitability benchmark. The contact lens and care-products segment, the core business, increased revenue 1.5% to ¥25.46bn and segment profit 17.2% to ¥2.90bn. Its segment margin improved to 11.4% from 9.9%, but the benefit was partly offset by a ¥1.62bn corporate-cost allocation, up 33.9% year on year. Operating cash flow of ¥2.07bn was 2.29x net income, supporting the cash realization of reported earnings. Nevertheless, cash conversion measured against EBITDA was weak at 0.57x, principally reflecting a ¥1.43bn inventory build and other working-capital demands. Reported free cash flow was negative ¥0.13bn, while operating cash flow less disclosed capital expenditure was positive ¥0.40bn; broader investing activity, including acquisitions and other investments, accounts for the difference. Cash and deposits declined 27.4% year on year to ¥5.17bn as capital investment, acquisition-related activity, debt repayment, leases, and dividends exceeded internally generated cash. The company completed acquisitions that added ¥0.73bn of provisional goodwill in the core segment, expanding its overseas contact-lens platform but creating execution risk. Full-year guidance implies a stronger Q4, particularly for sales and operating profit, while the Q3 cumulative profit figures are already ahead of a normal seasonal pace. The central forward issue is whether improved gross margins and segment profitability can be retained while reducing inventory intensity, refinancing short-term borrowings, and controlling central costs.
Profitability Analysis
The reported annualized DuPont ROE is 6.4%, composed of a 3.5% net profit margin, 0.642x asset turnover, and 2.81x financial leverage. This places the primary constraint on shareholder returns in modest operating/net profitability and slow asset utilization rather than an absence of leverage. Financial leverage is already meaningful, so further balance-sheet leverage would be a less attractive route to improving ROE. The largest positive operating change was gross-margin expansion: gross profit rose 4.7% versus revenue growth of 1.3%, lifting gross margin by about 145bp to 44.9%. Yet SG&A expenses rose 5.1% to ¥10.16bn, exceeding revenue growth and limiting operating-margin expansion to about 4bp, to 5.1%. This SG&A trend is a key operating-leverage concern, especially as corporate expenses rose to ¥1.62bn from ¥1.21bn. The core contact lens and care-products segment generated ¥25.46bn of revenue, up 1.5%, and ¥2.90bn of segment profit, up 17.2%; its segment margin rose approximately 153bp to 11.4%. The small Other segment, comprising eyeglasses and intraocular lenses, recorded revenue of ¥0.06bn, down 40.8%, and segment profit of ¥0.01bn versus near break-even profit in the prior year. The core business is therefore the contact lens and care-products segment, accounting for virtually all external sales and segment profit. Ordinary income growth outpaced operating-income growth because non-operating income increased, notably foreign-exchange gains of ¥0.20bn. The 5-factor DuPont tax burden was 0.650, reflecting a 34.6% effective tax rate, while the interest burden of 1.075 benefited from extraordinary income and indicates that pre-tax income exceeded EBIT. JGAAP goodwill amortization was ¥0.08bn, only 2.1% of EBITDA and therefore not a material distortion of earnings relative to IFRS reporters. EBITDA was ¥3.61bn and the EBITDA margin was 14.1%, substantially stronger than the EBIT margin because depreciation and amortization remain significant for this capital-intensive business. Annualized ROE of 6.4% remains below the 8% reference threshold, and the stated ROIC of 3.5% is below 5%, indicating that improved segment economics have not yet translated into satisfactory returns on the capital base.
Growth Assessment
Revenue growth of 1.3% was modest and below the 11.3% full-year sales-growth rate embedded in guidance. The Q3 cumulative sales progress rate was 69.0% of the ¥37.0bn full-year target, 6.0 percentage points below the standard 75% Q3 progress rate. Operating-income progress was 64.7% of the ¥2.0bn forecast, 10.3 percentage points below the 75% standard, requiring a substantial Q4 operating-income contribution. In contrast, ordinary-income progress was 81.9% of the ¥1.6bn forecast and profit attributable to owners progress was 82.3% of the ¥1.1bn target, both more than 6 percentage points ahead of the normal Q3 pace. The difference indicates that the full-year operating target requires stronger underlying trading in Q4, whereas below-the-line earnings have already benefited from favorable non-operating and extraordinary items. FX gains of ¥0.20bn represented 15.1% of ordinary income and contributed to the stronger ordinary-income trajectory; this is less recurring than gross-profit improvement. Extraordinary income of ¥0.81bn, although not large relative to revenue, also assisted pre-tax income and should not be extrapolated as operating momentum. The acquisition of Scotlens Holdings and its subsidiary, alongside the Shanghai acquisition, broadens the core segment’s distribution and market reach. The acquired businesses generated ¥0.73bn of provisional goodwill, and successful post-acquisition integration will determine whether the transaction supports sustainable growth. Inventory rose 31.1% year on year to ¥7.33bn, far faster than sales, which may reflect stock building for demand, acquisition consolidation, or a slower inventory cycle. The company’s capacity-investment profile is moderating: CapEx was ¥1.67bn and CapEx/depreciation was 0.72x, below replacement-and-growth parity. This supports near-term cash preservation but could constrain capacity renewal if sustained. Revenue sustainability should therefore be judged through Q4 delivery against the sales and operating-income targets, core-segment margin retention, and normalization of inventory growth.
Financial Health
Liquidity is tight rather than immediately deficient. The current ratio is 1.03x, above 1.0x but materially below the 1.5x healthy reference level, while the quick ratio is only 0.67x. Current assets of ¥21.16bn cover current liabilities of ¥20.51bn by only ¥0.65bn, leaving limited room for operational volatility. Short-term loans were ¥13.35bn and represented 70.8% of interest-bearing debt, creating a pronounced maturity mismatch and refinancing dependence. Cash of ¥5.17bn covered only 0.39x of short-term debt, explicitly signaling liquidity stress if bank facilities or rollover markets become less available. Interest-bearing debt totaled ¥18.85bn, while debt-to-equity was 1.81x, below the explicit 2.0x aggressive-leverage warning level but still elevated. Debt/capital was 49.9%, and debt/EBITDA was 5.22x, above the 4.0x high-leverage alert threshold. The high-leverage alert is rooted in debt materially exceeding EBITDA-based deleveraging capacity; its impact is reduced financial flexibility and heightened sensitivity to earnings or interest-rate pressure. Interest coverage was 4.50x on the EBIT measure, below the 5x strong benchmark but above the 3x concern threshold, while EBITDA interest coverage was 12.55x. This divergence underscores the burden of depreciation and amortization in assessing debt service. Cash and deposits decreased by ¥1.95bn year on year to ¥5.17bn, reflecting investment, financing outflows, and working-capital consumption. Inventories increased by ¥1.74bn year on year to ¥7.33bn and now represent 13.8% of total assets, tying up liquidity. Goodwill rose from ¥0.37bn to ¥1.05bn and intangible assets from ¥0.92bn to ¥1.58bn following acquisitions; these increases are manageable because goodwill/equity is only 5.6% and goodwill/EBITDA is 0.29x. PPE is substantial at ¥28.18bn, or 53.1% of total assets, consistent with a capital-intensive manufacturing platform. Lease obligations total ¥6.75bn, comprising ¥1.74bn current and ¥5.05bn non-current obligations, and are an additional fixed financing commitment relevant to liquidity management. Net defined-benefit liability was ¥2.97bn, another long-term obligation to monitor alongside interest-bearing debt.
Notable B/S Changes
Goodwill: +¥0.68bn (+181.7%) to ¥1.05bn - acquisitions of Scotlens Holdings and Shanghai Huan Ying increased M&A-related asset exposure; provisional purchase-price allocation requires monitoring, though goodwill/equity remains low at 5.6%. Intangible assets: +¥0.66bn (+71.4%) to ¥1.58bn - acquisition-related and intangible-asset expansion increases future amortization and integration dependence, but remains only 3.0% of total assets. Inventories: +¥1.74bn (+31.1%) to ¥7.33bn - growth far exceeded revenue growth, reducing liquidity and underpinning high inventory-days and cash-conversion-cycle alerts. Cash and deposits: -¥1.95bn (-27.4%) to ¥5.17bn - investment, financing, and working-capital outflows reduced the cash buffer against ¥13.35bn of short-term loans.
Cash Flow Quality
Operating cash flow was ¥2.07bn, equal to 2.29x net income of ¥0.91bn, so reported earnings converted into operating cash flow on this measure. The accruals ratio of negative 2.2% is also consistent with acceptable accrual quality rather than aggressive non-cash income recognition. However, the low-cash-conversion alert is valid: OCF/EBITDA was 0.57x, below the 0.7x warning threshold. Its root cause is working-capital absorption, led by a ¥1.43bn increase in inventories and a ¥0.27bn increase in advance payments, alongside tax and financing-related cash needs. The impact is that EBITDA does not yet translate into cash at a rate consistent with a strong self-funded growth model. Reported free cash flow was negative ¥0.13bn, indicating that aggregate operating and investing demands exceeded operating cash generation during the period. Operating cash flow less disclosed CapEx was positive ¥0.40bn, but acquisition-related and other investing expenditures reduced cash generation at the broader free-cash-flow level. CapEx was ¥1.67bn, equal to 72% of depreciation and amortization, which is below the 1.0x expansion/replacement threshold but above the 0.7x underinvestment warning threshold. Cash declined ¥2.11bn in the period after ¥2.20bn of investing outflows and ¥1.97bn of financing outflows. The high-inventory-days alert of 175 days identifies a very slow inventory cycle relative to the 90-day warning benchmark. A second high-inventory-days alert of 143 days likewise remains well above the 60-day manufacturing benchmark; irrespective of methodology, both measures indicate excess capital tied up in stock. Finished goods were ¥7.33bn, while raw materials were ¥1.25bn and work in process ¥0.42bn, pointing to finished goods as the principal inventory concentration. The long-cash-conversion-cycle alert of 212 days is therefore rooted primarily in stock holding rather than receivable collection. This is not typical of an efficient manufacturing cycle and heightens the risk of discounting, obsolescence, or further cash absorption if sales do not accelerate. Management’s near-term cash-flow priorities are inventory normalization, disciplined acquisition integration, and preservation of operating cash for debt servicing and essential investment.
Dividend Sustainability
The full-year dividend forecast is ¥15.00 per share. Against forecast EPS of ¥36.34, the implied dividend payout ratio is approximately 41.3%, within the sub-60% sustainability reference range. The Q2 dividend per share was ¥0, so the indicated shareholder distribution is concentrated in the year-end payment rather than supported by an interim dividend. Forecast profit attributable to owners of ¥1.10bn would cover the implied full-year cash dividend of approximately ¥0.45bn. Operating cash flow of ¥2.07bn also covered cash dividends paid of ¥0.45bn during the nine-month period. However, reported free cash flow was negative ¥0.13bn because investment and acquisition-related cash outflows were elevated. Accordingly, the forecast dividend appears earnings-covered and operating-cash-flow-covered, but its resilience depends on reducing working-capital cash consumption and maintaining access to refinancing. No share repurchase was indicated for the current period, so the assessment is based on the dividend payout ratio rather than a total return ratio. Given debt/EBITDA of 5.22x, cash/short-term debt of 0.39x, and substantial short-term borrowings, debt reduction and liquidity preservation remain important competing calls on cash. The current ¥15.00 annual dividend outlook is therefore supportable on forecast earnings but should be assessed alongside Q4 operating delivery, inventory liquidation, and short-term debt rollover conditions.
Risk Assessment
Business risks include Demand and mix risk in the contact lens and care-products core business: Q3 revenue growth was only 1.5% in the core segment, while full-year guidance requires a stronger Q4 sales contribution., Inventory and obsolescence risk: inventories rose 31.1% year on year to ¥7.33bn, with alerts showing inventory days of 175 days and 143 days; both are materially above manufacturing benchmarks and may require discounting or provisions if sell-through weakens., Margin-retention risk: the gross margin improved about 145bp, but SG&A rose 5.1% against 1.3% sales growth and corporate costs increased 33.9%, risking erosion of the limited 5.1% operating margin., M&A integration risk: Scotlens and Shanghai acquisitions created ¥0.73bn of provisional goodwill in the core segment. Purchase-price allocation remains provisional, and realization of commercial and operational synergies is necessary to validate the acquisition value., Foreign-exchange risk: ¥0.20bn of FX gains supported ordinary income, equivalent to 15.1% of ordinary income, exposing reported earnings to currency reversals., Manufacturing-specific product-quality risk: product warranty provision was ¥0.10bn; quality, recall, regulatory, and supply-chain disruptions can affect customer trust and margins in vision-care products..
Financial risks include High leverage alert: debt/EBITDA of 5.22x exceeds the 4.0x alert threshold. This debt burden limits flexibility for further acquisitions, capacity investment, or shareholder distributions if earnings weaken., Refinancing-risk alert: 70.8% of debt is short term, with ¥13.35bn of short-term loans. The reliance on short-term facilities creates material rollover exposure., Liquidity-stress alert: cash/short-term debt of 0.39x means on-hand cash covers less than half of short-term loans. The current ratio of 1.03x and quick ratio of 0.67x reinforce constrained near-term liquidity., Low cash-conversion alert: OCF/EBITDA of 0.57x is below 0.7x, reflecting heavy working-capital usage and weakening the cash deleveraging profile., Interest-rate and debt-service risk: EBIT interest coverage of 4.50x is adequate but below the 5x strong benchmark; higher borrowing costs or weaker EBIT would narrow headroom., Capital-efficiency alert: stated ROIC of 3.5% is below 5%, suggesting invested capital is not yet earning an adequate return despite leverage..
Key concerns include Highest priority: refinancing and liquidity, given a 70.8% short-term debt ratio, 0.39x cash/short-term debt, and only ¥0.65bn of positive working capital., High priority: inventory normalization and cash-conversion improvement, as long inventory days and a 212-day cash conversion cycle tie up capital and can impair margins., High priority: achievement of the Q4 operating plan, because Q3 operating-income progress of 64.7% is 10.3 percentage points below the standard 75% pace., Medium priority: central-cost discipline, since corporate expenses increased faster than revenue and offset core-segment profit improvement., Medium priority: acquired-business integration and provisional goodwill valuation, although goodwill remains modest relative to equity and EBITDA..
Investment Implications
Key takeaways include Gross-margin and core-segment-margin improvement are the principal positive operating developments, with the core segment margin rising to 11.4%., Profit attributable to owners grew 9.8%, faster than sales, but part of the outperformance came from FX gains and extraordinary income rather than solely recurring operations., OCF exceeded net income, but low OCF/EBITDA conversion, elevated inventory, and reported negative free cash flow limit the quality of cash generation., Leverage is elevated at 5.22x debt/EBITDA, while short-term debt concentration and low cash coverage make refinancing capacity strategically important., The ¥15 annual dividend forecast implies a moderate 41.3% payout ratio, but capital allocation flexibility is constrained by liquidity and deleveraging needs..
Metrics to watch include Q4 revenue and operating income versus the ¥37.0bn and ¥2.0bn full-year targets, Core contact lens and care-products segment revenue growth and segment margin, SG&A and corporate-cost growth relative to revenue growth, Inventory balance, inventory days, and the cash conversion cycle, Operating cash flow/EBITDA and reported free cash flow, Short-term debt rollover, cash/short-term debt, debt/EBITDA, and interest coverage, Integration performance and final purchase-price allocation for the Scotlens and Shanghai acquisitions.
Regarding relative positioning, Seed exhibits a strong gross margin and improving core-segment profitability, but its annualized 6.4% ROE and stated 3.5% ROIC are below preferred capital-efficiency levels. Relative to a conservatively financed manufacturer, the company carries a more leveraged and less liquid profile, with inventory management and refinancing capacity more decisive than headline earnings growth.